Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272569 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL4512442 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL94287 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL14134607 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL16546828 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL21439801 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL316251 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL5916068 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL14770369 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL | |
| SCHEMBL10710689 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRCA2KDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052465-A1 | CHEMICAL COMPOUNDS | Resman AS (NO) | 2016-08-10 | — | — | EP | claimed |
| US-20160214930-A1 | CHEMICAL COMPOUNDS | RESMAN AS (NO) | 2016-07-28 | — | — | US | claimed |
| WO-2015047105-A1 | CHEMICAL COMPOUNDS | RESMAN AS (NO) | 2015-04-02 | — | — | WO | claimed |
| US-20150094240-A1 | CHEMICAL COMPOUNDS | RESMAN AS (NO) | 2015-04-02 | — | — | US | claimed |
| US-12597635-B2 | Electrochemical device | MURATA MANUFACTURING CO., LTD. (JP) | 2026-04-07 | — | — | US | disclosed |
| US-12095081-B2 | Electrolytic solution and electrochemical device | MURATA MANUFACTURING CO., LTD. (JP) | 2024-09-17 | — | — | US | disclosed |
| US-20240014378-A1 | POSITIVE ELECTRODE AND ELECTROCHEMICAL DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| US-20230223525-A1 | ELECTROCHEMICAL DEVICE | MURATA MANUFACTURING CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-11619842-B2 | Liquid crystal display device including liquid crystal capsule and method of fabricating the same | LG DISPLAY CO., LTD. (KR) | 2023-04-04 | — | — | US | disclosed |
| US-11619842-B2 | Liquid crystal display device including liquid crystal capsule and method of fabricating the same | LG DISPLAY CO., LTD. (KR) | 2023-04-04 | — | — | US | disclosed |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20120302730-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2012-11-29 | — | — | US | disclosed |
| US-20120247562-A1 | DYE-SENSITIZED SOLAR CELL AND METHOD OF MANUFACTURING THE SAME | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-2495797-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY | Asahi Glass Company, Limited (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-8258259-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2012-09-04 | — | — | US | disclosed |
| US-20120214073-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERIES, AND SECONDARY BATTERY | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20110123982-A1 | NUCLEIC ACID BASED FLUORESCENT SENSOR FOR COPPER DETECTION | UNITED STATES DEPARTMENT OF ENERGY | 2011-05-26 | — | — | US | disclosed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | disclosed |
| EP-0553353-A1 | 2'-MODIFIED ERYTHROMYCIN OR DERIVATIVE THEREOF | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1993-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, ARRB1 | ALDH1A1 398/4885TSHR 2123/4885CA2 2415/4885 |
| US-20160214930-A1 | CHEMICAL COMPOUNDS | PTGES, PTGIS, PTGFR | ALDH1A1 1333/4885TSHR 3608/4885CA2 4398/4885 |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | MICA, PICALM, CLTB | ALDH1A1 4603/4885TSHR 3447/4885CA2 3784/4885 |
| US-20110123982-A1 | NUCLEIC ACID BASED FLUORESCENT SENSOR FOR COPPER DETECTION | RNGTT, DNASE1, DDX1 | ALDH1A1 566/4885TSHR 3188/4885CA2 1360/4885 |
| US-20120302730-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | MICA, PICALM, CLTB | ALDH1A1 4603/4885TSHR 3447/4885CA2 3784/4885 |
| US-20150094240-A1 | CHEMICAL COMPOUNDS | PTGES, PTGIS, PTGFR | ALDH1A1 1333/4885TSHR 3608/4885CA2 4398/4885 |
| US-20230077680-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | ALDH1A1 1891/4885TSHR 719/4885CA2 2461/4885 |
| US-12597635-B2 | Electrochemical device | CLCN2, HCN4, SLC26A3 | ALDH1A1 2350/4885TSHR 1300/4885CA2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.